The past, present and future of antimycotic combination therapy

Mycoses

Volumn 42, Issue 5-6, 1999, Pages 355-370

  Polak, Annemarie ^a  

^a NONE   (Switzerland)

Author keywords

Antimycotic chemotherapy; Combination therapy

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; AZITHROMYCIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; GENTAMICIN; GRISEOFULVIN; IMIDAZOLE DERIVATIVE; IMMUNOMODULATING AGENT; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCOSIS; DRUG POTENTIATION; DRUG TOLERABILITY; FUNGICIDAL ACTIVITY; HUMAN; IMMUNOMODULATION; MOUSE; MYCOSIS; NONHUMAN; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; REVIEW; TOPICAL DRUG ADMINISTRATION; VIRULENCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIFUNGAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MICE; MYCOSES;

EID: 0032882043     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1439-0507.1999.00475.x     Document Type: Review

References (163)

1. 1 Medoff, G., Kobayashi, G. S., Kwang, C. N. et al. (1971) Potentiation of rifampicin and flucytosine as antifungal antibiotics by amphotericin B. Proc. Soc. Exp. Biol. Med. 138, 571-574.
2. 2 Polak, A. (1978)Synergism of polyene antibiotics with 5-fluorocytosine. Chemotherapy 24, 2-16.
3. 3 Polak, A. (1980) Détermination de la synergie entre la 5-fluorocytosine et 3 dérivées de l'imidazole au moyen de différents modeles in vitro et in vivo. Bull. Soc. Franç. Mycol. Méd. 9, 263-268.
4. 4 Polak, A. (1989) Combination therapy for systemic mycosis. Infection 17, 203-209.
5. 5 Martin, E., Maier, F. & Bikadi, S. (1994) Antagonistic effects of flueonazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob. Agents Chemother. 38, 1331-1338.
6. 6 Nguyen, M. H., Barchiesi, F., McGough, D. A., Yu, V. L. & Rinaldi, M. G. (1995) In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 39, 1691-1695.
7. 7 Wolfe, E. J., Klepser, M.-E. & Pfaller, M. A. (1997) Antifungal dynamics of amphotericin B and fluconazole in combination against Candida albicans: effect of exposure time. Pharmacotherapy 17, 189.
8. 8 Vazquez, J. A., Arganoza, M. T. Vaishampayan, J. K. & Akins, R. A. (1996) In vitro interaction between amphotericin B and azoles in Candida albicans. Antimicrob. Agents Chemother. 40, 2511-2516.
9. 9 Cao, B., Tsang, P. W., Samaranayke, L. P. & Wang, J. (1996) A. disc plate assay for characterization of the effect of interaction between polyenes and azoles on growth of Candida albicans CA12. Microbios 87, 161-167.
10. 10 Ghannoum, M. A., Fu, Y., Ibrahim, A. S., et al. (1995) In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob. Agents Chemother. 39, 2459-2465.
11. 11 Polak, A. (1993) Combination of amorolfine with various antifungal drugs in dermatomycosis. Mycoses 36, 43-49.
12. 12 Polak, A. (1995) Mechanism of action and combination therapy. J. Euro. Acad. Dermatol. Vener. 4 (Suppl. 1), S11-S16.
13. 13 Barchiesi, F., Falconi di Francesco, L. & Scalise, G. (1997) In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibilities to azoles. Antimicrob. Agents Chemother. 41, 1812-1814.
14. 14 Barchiesi, F., Falconi di Francesco, L., Compagnucci, P., Arzeni, D., Giacometti, A. & Scalise, G. (1998) In vitro interactions of terbinafine with amphotericin B, fluconazole and itraconazole against Candida albicans. J. Antimicrob Chemother. 41, 59-65.
15. 15 Pore, R. S. (1992) Amphotericin B. synergy testing by FCST. Curr. Microbiol. 24, 171-177.
16. 16 Padhye, A. A., Garg. A. K., Ahmad, H. & Moledina, N. (1993) In vitro sensitivity of medically significant Fusarium species. Sixth Eur. Congress of Clin Microbiol and Infect. Dis. Sevilla, Spain. Abstract 950.
17. 17 Clancy, C. J. & Nguyen, M. H. (1998) The combination of amphotericin B and azithromycin as a potential therapeutic approach to fusariosis. J. Antimicrob. Chemother 41, 127-130.
18. 18 Franzor, S. P. & Casadevall, A. (1997) Pneumocandin L.-743872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Amtimicrob Agents Chemolher. 41, 331-336.
19. 19 Polak, A., Scholer, H. J. & Wall, M. (1982) Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy 28, 461-479.
20. 20 Polak, A. (1987) Combination therapy in experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice (5FC in combination with new triazoles derivatives). Chemotherapy 33, 381-395.
21. 21 Thaler, M., Bacher, J., O'Leary, T. & Pizzo, P. A. (1988) Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. J. Infect. Dis. 158, 80-88.
22. 22 Hughes, C. E., Peterson, L. R., Beggs, W. H. & Gerding, D. N. (1986) Ketoconazole and flucytosine alone and in combination against Candida spp. in a neutropenic site in rabbits. J. Antimicrob. Agents Chemother 18, 65-72.
23. 23 Polak, A. (1987) 5 fluorocytosine et associations. Ann. Biol. Clin. 45, 669-671.
24. 24 Walsh, T. J., Aoki, S., Mechinaud, F., et al. (1990) Effects of preventive, early and late antifungal chemotherapy with fluconazole in different granulocytopenic models of disseminated candidiasis. J. Infect. Dis. 161, 755-760.
25. 25 Walsh, T. J., Van Cutsem, J., Polak, A. & Graybill, J. R. (1992) Immunomodulation and antifungal therapy of experimental invasive candidosis, histoplasmosis and aspergillosis: recent advances and concepts. J. Med. Vet. Mycol. 30 (Suppl 1), 223-240.
26. 26 Polak, A. & Schaffner, A. (1989) A. new experimental model of localised candidosis for the study of antifungal chemotherapy. Mycoses 32, 398-404.
27. 27 Polak, A. (1989) A new experimental model of localised candidosis for the study of antifungal chemotherapy. Congress Mycoses in AIDS, Paris.
28. 28 Iovannitti, C., Negroni, R., Bava, J., Finquelivich, J, & Kral, M. (1995) Itraconazole and flucytosine + itraconazole combination in the treatment of experimental cryptococcosis in hamsters. Mycoses 38, 449-452.
29. 29 Atkinson, B. A., Bouthet, C., Bocanegra, R., Correa, A., Luther, M. F. & Graybill, J. R. (1995) Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immuno-compromised mice. J. Antimicrob. Chemother 35, 631-640.
30. 30 Allendoerfer, R., Marquis, A. J., Rinaldi, M. G. & Graybill, J. R. (1991) Combined therapy with fluconazole and flucytosine in murine cryptococcosis. Antimicrob. Agents Chemother. 35, 726-729.
31. 31 Ding, J. C., Bauer, M., Diamond, D. M., et al. (1997) Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob. Agents Chemother. 41, 1589-1593.
32. 32 Larsen, R. A., Bauer, M., Weiner, J. M., et al. (1996) Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob. Agents Chemother. 40, 2178-2182.
33. 33 Larsen, R. A., Bauer, M. M., Ding, J. C., et al. (1997) novel method for the design of clinically relevant animal models of AIDS associated cryptococcal meningitis. Clin. Infect. Dis. 25, 356.
34. 34 Nguyen, M. H., Najvar, L. K., Yu, C. Y. & Graybill, J. R. (1997) Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicr. Agents Chemother. 41, 1120-1123.
35. 35 Bava, A. J. & Negroni, R. (1994) Flucytosine + fluconazole association in the treatment of a murine experimental model of cryptococcosis. Rev. Inst. Med. Trop. Sao Paulo 36, 551-554.
36. 36 Kartalija, M., Kaye, K., Tureen, J. H., et al. (1996) Treatment of experimental cryptococcal meningitis with fluconazole: Impact of dose and addition of flucytosine on mycological and pathophysiologic outcome. J. Infect. Dis 173, 1216-1221.
37. 37 Sugar, A. M., Hitchcock, C. A., Troke, P. F. & Picard, M. (1995) Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Chemother. 39, 598-601.
38. 38 Schaffner, A. & Frick, P. G. (1985) The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J. Infect. Dis. 151, 902-910.
39. 39 Polak, A. & Schaffner, A. (1984) Association des antimycotiques dans les mycoses expérimentales. Médicine Maladies Infecteuse 14, 553-557.
40. 40 Sugar, A. M. & Xiu Ping Liu (1998) Interaction of itraconazole with amphotericin B in the treatment of invasive candidiasis. J. Infect. Dis. 177, 1660-1663.
41. 41 Sanati, H., Ramos, C., Bayer, A. S. & Ghannoum, M. (1997) Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenicmouse and infective-Candida endocarditis rabbit model. Antimicrob. Agents Chemother. 41, 1345-1348.
42. 42 Anaissie, E. J., Hachem, R. Karyotakis, N. C. Gokaslan, A., Dignani, M. C. & Stephans, L. C. (1994) Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichorporonosis. Antimicrob. Agents Chemother. 38, 2541-2544.
43. 43 Kamberi, P., Atsuro, H., Takayoshi, T. & Masaru, N. (1998) Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice. Chemotherapy 44, 55-62.
44. 44 Polak, A. (1988) Combination therapy with antifungal drugs. Mycoses 31 (Suppl. 2), 45-53.
45. 45 Bennett, J. E., Dismuskes, W. E., Duma, J. R., et al. (1979) A. comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. New Engl. J. Med. 301, 127-131.
46. 46 Dismuskes, W., Cloud, G., Gallis, H., et al. (1987) Treatment of cryptococcal meningitis with combination of amphotericin B and flucytosine for four as compared to six weeks. New Engl. J. Med. 317, 334-341.
47. 47 Stamm, A. M., Diasio, R. B., Dismuskes, W. E., et al. (1987) Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am. J. Med. 83, 36-242.
48. 48 Kauffmann, C. A. & Frame, P. T. (1977) Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob. Agents Chemother. 11, 244-247.
49. 49 Hoeprich, P. D. (1995) Antifungal Chemotherapy. Prog. Drug Research 44, 88-127.
50. 50 Heidemann, H. T., Gerkens, J. F., Spickard, W. A., Jackson, E. K. & Branch, R. A. (1983) Amphotericin B. nephrotoxicity in human decreased by salt repletion. Am. J. Med. 75, 476-481.
51. 51 Heidemann, H. T. & Brune, K. H. (1987) Verhinderung der Amphotericin B Nephrotoxizität durch parenteral verabreichtes Flucytosin. Therapiewoche 44, 4158-4166.
52. 52 Polak, A. (1989) Die antimykatische Chemotherapie opportunistischer Pilzinfektionen. Habilitationsarbeit. Basel: Editiones Roche.
53. 53 Mitchell, D. H., Soorell, T. C., Allworth, A. M., et al. (1995) Cryptococcal disease of the CNS in immunocompetent hosts: Influence of cryptococcal variety on clinical manifestation and outcome. Clin. Infect. Dis. 20, 611-616.
54. 54 Francis, P. & Walsh, T. J. (1992) Evolving role of flucytosine in immunocompromised patients: new insight into safety, pharmacokinetics and antifungal therapy. Clin. Infect. Dis. 15, 1003.
55. 55 Saag, M. S., Powderly, W. G., Cloud, G. A., Robinson, R. et al. (1992) Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. New Engl. J. Med. 326, 83-89.
56. 56 White, M., Cirrincione, C., Blevins, A. & Armstrong, D. (1992) Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J. Infect. Dis. 165, 960-963.
57. 57 Van der Horst, Ch. M., Saag, M. S., Cloud, G. A., et al. (1997) Treatment of cryptococcal meningitis associated with the acquired immunodefficency syndrome. New Engl. J. Med. 337, 15-21.
58. 58 Glasmacher, A., Just-Nübling, G. & Molitor, E. (1998) Therapie invasiver Mykosen bei neutropenischen Patienten mit hämatologischen Systemerkrankungen. Deutsch. Med. Zschr. 123, 191-194.
59. 59 Just-Nübling, G. (1999) Mykosen innerer Organe, Kapitel 91. In press.
60. 60 Powderly, W. G. (1992) Therapy for cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 14 (Suppl. 1), S 54-59.
61. 61 Ruf, B. (1990) Cryptococcose bei AIDS. Therapeutische Konzepte. Mycoses 33 (Suppl. 1), 55-64.
62. 62 Seaton, R. A. (1996) The management of cryptococcal meningitis in Papua New Guinea. P.N.G. Med. J. 39, 67-73.
63. 63 Jaruratanasirikul, S. (1996) Amphotericin B. with or without flucytosine followed by fluconazole as primary therapy for cryptococcal meningitis in patients with AIDS. Southeast Asian J. Trop. Public. Health 27, 719-723.
64. 64 Parisi, A. M., Malfitano, A., Bruno, R., et al. (1997) Efficacy of a short-term amphotericin B + flucytosine combination therapy followed by itraconazole monotherapy in acute and chronic AIDS-associated cryptococcosis. Mycoses 40, 203-207.
65. 65 Larsen, R. A., Leal, M. A. & Chan, L. S. (1990) Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomised trial. Ann. Intern. Med. 113, 183-187.
66. 66 De Gans, J., Portegies, P., Eecftinck Schattenkerk, J. K., van Boxtel, C. J., Van Ketel, R. J. & Stam, J. (1992) Itraconazole compared with amphotericin B in AIDS patients with cryptococcal meningitis. AIDS 6, 185-190.
67. 67 Larsen, R. A., Bozette, S. A. Jones, B. E., et al. (1994) Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 19, 741-745.
68. 68 Witt, M. D., Lewis, R. J., Larsen, R. A., et al. (1996) Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin. Infect. D. 22, 322-328.
69. 69 Mayanja Kizza, H., Oishi, K., Mitarai, S., et al. (1998) Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin. Infect. Dis. 26, 1362-1366.
70. 70 Chotmongkol, V. & Jitpimolmard, S. (1994) Treatment of cryptococcal meningitis with combination itraconazole and flucytosine. J. Med. Assoc. Thai 77, 253-256.
71. 71 Singh, N., Gayowski, T. & Marino, J. R. (1998) Successful treatment of disseminated cryptococcosis in a liver transplant recipient with fluconazole and flucytosine, an all oral regimen. Transpl. Int. 11, 63-65.
72. 72 Yamamoto, Y., Maesaki, S., Kakeya, H., et al. (1997) Combination therapy with fluconazole and flucytosine for pulmonary cryptococcosis. Chemotherapy 43, 436-441.
73. 73 Viviani, M. A. (1995) Flucytosine what is the future? J. Antimicrob. Chemother. 35, 241-244.
74. 74 Just-Nübling, G. (1994) Die Therapie der Candidose und Cryptococcose bei AIDS. Mycoses 37 (Suppl. 2), 56-63.
75. 75 Cottagnoud, P., Rossi, M., Ross, J. & Neftel, K. (1995) Amphotericin B. with flucytosine and fluconazole in cryptococcal meningitis. Infect. Dis. Clin. Pract. 4, 456-458.
76. 76 Chotmongkol, V. & Jitpimolmard, S. (1995) Treatment of cryptococcal meningitis with triple combination of amphotericin B, flucytosine and itraconazole. Southeast Asian J. Trop. Med. Public Health 26, 381-383.
77. 77 Chotmongkol, V., Sukeepaisarncharoen, W. & Thavornpitak, Y. (1997) Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and flucytosine in the treatment of cryptococcal meningitis in AIDS. J. Med. Assoc. Thai 80, 416-423.
78. 78 Verveij, P. E., Donnelly, J. P., Kullberg, B. J., Meis, J. F. & Pauw, G. M. (1994) Amphotericin B versus amphotericin B plus flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 22, 81-85.
79. 79 Armstrong, D. (1993) Treatment of opportunistic fungal infections. Clin. Infect. Dis. 16, 1-7.
80. 80 Hawkins, C. & Armstrong, D. (1984) Fungal infections in the immunocompromised host. Clin. Haematol. 13, 343-373.
81. 81 Haron, E., Feld, R., Tuffnell, B., Patterson, B., Hasselback, R. & Matlow, A. (1987) Hepatic candidiasis: an increasing problem in immunocompromised patients. Am. J. Med. 83, 17-26.
82. 82 Kujath, P., Lerch, K., Kochendorfer, P. & Boos, C. (1993) Comparative study of eflicacy of fluconazole versus amphotericin B/flucytosine in surgiral patients with systemic mycoses. Infection 21, 376-382.
83. 83 Walsh, T. & Pizzo, P. A. (1989) Fungal infections in granulocytopenic patients: current approaches to classification, diagnosis and treatment. In: Holmberg, R. & Meyer, D. (eds) Diagnosis and Therapy of Systemic Fungal Infections. New York: Raven Press, pp. 47-70.
84. 84 Van Eiff, M., Fahrenkamp, A., Roos, N., Fegeler, W. & van de Loo, J. (1990) Hepatosplenic candidosis - a late manifestation of Candida septicemia. Mycoses 33, 283-290.
85. 85 Walsh, T. J., Whitecomber, P. O., Revankar, S. G. & Pizzo, P. A. (1995) Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 76, 2357-2362.
86. 86 Faix, R. G., Feick, H. J., Frommelt, P. & Snider, A. R. (1990) Successful medical treatment of Candida parapsilosis endocarditis in a premature infant. Am. J. Perinatol. 7, 272-275.
87. 87 Faix, R. G. (1984) Systemic Candida infection in infants in intensive care nurseries: high incidence of central nervous system involvement. J. Pediatr. 105, 616-632.
88. 88 Ho, N. K. (1985) Systemic candidiasis in premature infants. Experience with drug treatment. Ann. Acad. Med. Singapore 14, 587-590.
89. 89 Zenker, P. N., Rosenberg, E. M., Van Dyke, R. B., Rabalais, G. P. & Daum, R. S. (1992) Successful medical treatment of presumed Candida endocarditis in critically ill infants. J. Pediatr. 119, 472-477.
90. 90 Filler, S. G. & Edwards, J. E. (1995) When and how to treat serious candidal infections: concepts and controversies. Curr. Clin. Topics Infect. Dis. 15, 1-18.
91. 91 Nguyen, M. H. & Yu, V. L. (1995) Meningitis caused by Candida species: an emerging problem in neurosurgical patients. Clin. Infect. Dis. 21, 323-327.
92. 92 Smego, R. A., Perfect, J. R. & Durack, D. T. (1984) Combined therapy with amphotericin and 5-fluorocytosine for Candida meningitis. Rev. Infect. Dis. 6, 791-801.
93. 93 Casado, J. L., Quereda, C., Oliva, J., et al. (1997) Candidal meningitis in HIV-infected patients: analysis of 14 cases. Clin. Infect. Dis. 2, 673-676.
94. 94 Gilbert, H. M., Peters, E. D., Lang, S. J. & Hartman, B. J. (1996) Successful treatment of fungal prosthetic valve endocarditis: case report and review. Clin. Infect. Dis. 22 (2), 348-354.
95. 95 Cheng, I. K. P., Fang, G. X., Chan, T. M. & Chan, M. K. (1989) Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment. Quart. J. Med. 71 (265), 407-416.
96. 96 Slingenmeyer, A., Laroche, B., Stec, F., Canaud, B., Beraud, J. J. & Minon, C. (1987) Oral ketocoanzole plus intraperitoneal 5-fluorocytosine as the sole treatment of fungal peritonitis. Perit. Dial. Bull. 4 (Suppl.), S60.
97. 97 Struijk, D. G., Krediet, R. T., Boeschoten, E. W., Rietra, P. J. & Arisz, L. (1987) Antifungal treatment of Candida peritonitis in continuous ambulatory peritoneal dialysis patients. Am. J. Kidney Dis. 9, 66-70.
98. 98 Abele-Horn, M., Kopp, A., Sternberg, U. et al. (1996) A. randomised study comparing fluconazole with amphotericin B/flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 24, 426-432.
99. 99 Kujath, P., Boos, C. & Eckmann, C. (1998) Treatment of Candida peritonitis. Br. J. Surg. 85, 861.
100. 100 Dupont, B. & Drouhet, E. (1985) Cutaneous, ocular and osteoarticular candidiasis in heroin addicts: new clinical and therapeutic aspects in 38 patients. J. Inf. Dis. 152, 577-591.
101. 101 McGray, E., Rampell, N., Solomon, S. L., Bond, W. W., Martone, W. J. & O'Day, D. (1986) Outbreak of Candida parapsilosis endophthalmitis after cataract extraction and intraocular lens implantation. J. Clin. Microbiol. 24, 625-628.
102. 102 Stern, W. H., Tamura, E., Jacobs, R. et al. (1985) Epidemic postsurgical Candida parapsilosis endophthalmitis. Opthalmology 92, 1701-1709.
103. 103 Schmid, S., Mertenet, A. C. & Oelz, O. (1991) Candida endophthalmitis: clinical presentation, treatment and outcome in 23 patients. Infection 19, 21-24.
104. 104 Burch, P. A., Karp. J. E. & Mery, J (1987) Favorable outcome of invasive aspergillosis in patients with acute leukemia. J. Clin. Oncol. 5, 1985-1989.
105. 105 Polak, A. (1997) Antifungal therapy, an everlasting battle. In: Jucker, E. (ed.) Progress in Drug Research 49, 219-318.
106. 106 Negroni, R., Robles, A. M. & Arechavala, A. (1995) Disseminated phacohyphomycosis caused by Exophiala spinifera. Revista Argent. Micol. 18, 2-10.
107. 107 Filler, S. G. & Edwards, J. E. (1995) When and how to treat serious candial infections: concepts and controversies. Curr. Clin. Top. Infect. Dis. 15, 1-18.
108. 108 Graybill, J. R. (1997) Can we agree on the treatment of candidiasis? Clin. Infect. Dis. 25, 60-63.
109. 109 Graybill, J. R. (1996) The future of antifungal therapy. Clin. Infect. Dis. 22 (Suppl. 2), S166-S177.
110. 110 Katner, H. P., Singh, S. & Zimmer, S. (1996) Combination of amphotericin B and azoles in the treatment of filamentous fungal infections, report of 3 cases. Abstract. Gen. Meet. Am. Soc. Microbiol. Meet 96, 79.
111. 111 Sugar, A. M. (1995) Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob. Agents Chemother. 39, 1907-1912.
112. 112 Polak. A. & Hartman, P. G. (1991) Antifungal chemotherapy - are we winning? In: Jucker, E. (ed.) Progress in Drug Research 37, 181-269.
113. 113 Polak, A. (1992) Virulence of Candida albicans mutants. Mycoses 35, 9-16.
114. 114 Barret-Bee, K., Hayes, Y., Wilson, R. G. & Ryley, J. F. (1985) A. comparison of phospholipase activity, cellular adherence and pathogenicity of yeasts. J. Gen Microb 131, 1217-1221.
115. 115 Kwong-Chung, K. J., Lehman, C., Good, C. & Magee, P. T. (1985) Genetic evidence for the role of extracellular proteinase in virulence of Candida albicans. Infect. Immun. 49, 571-575.
116. 116 Rüchel, R. (1981) Properties of purified proteinase from the yeast Candida albicans. Biochim. Biophys. Acta 659, 99-113.
117. 117 Rüchel, R., Ritter, B. & Schaffrinski, M. (1990) Modulation of experimental systemic murine candidosis by intravenous pepstatin. Zbl. Bakt. 273, 391-403.
118. 118 Hube, B., Turver, C. J., Odds, F. C., et al. (1991) Sequence of the Candida albicans gene encoding the secretory aspartate proteinase. J. Med. Vet Mycol. 29, 129-132.
119. 119 Händ, H., Kirsch, R. & Schmidts, H.-L. & Kottmann (1995) New systemically active antimycotics from the beta-blocker category. Mycoses 38, 251-264.
120. 120 Pucetti, P., Menacci, A., Cencei, E., Spaccapelo, R., Mosci, P. & Enssle, K. H. (1994) Cure of murine candidiasis by recombinant soluble interleukin. J. Infect. Dis 269, 1325.
121. 121 Feldmesser, M., Mukherjee, J. & Casadevella, A. (1996) Combination of flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro. J. Antimicrob. Chemother. 37, 617-622.
122. 122 Herrmann, J. L., Dubois, N., Fourgeaud, M., Basset, D. & Lagrange, P. H. (1994) Synergic inhibitory activity of amphotericin B and gamma interferon against intracellular Cryptococcus neoformans in murine macrophages. J. Antimicrob. Chemother. 34, 1051-1058.
123. 123 Zhang, T., Kawakhami, K., Oureshi, M. H., Kurimoto, M. & Saitoi, A. (1997) Interleukin-12 and interleukin-18 synergistically induce the fungicidal activity of murineperitoncal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect. Immun. 65, 3594-3599.
124. 124 Natarajan, U., Randhawa, N., Brummer, E. & Stevens, D. A. (1998) Effect of granulocate-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophages and synergy with fluconazole. J. Med. Microbiol. 47, 359-363.
125. 125 Natarajan, U., Brummer, E. & Stevens, D. A. (1997) Effect of granuloryte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole. Antimicrob. Agents Chemother 41, 1575-1578.
126. 126 Vora, S. M., Chauhanm, S., Brummer, E. & Stevens, D. A. (1998) Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob. Agents Chemother. 42, 2299-2303.
127. 127 Brummer, E., Nassar, F. & Stevens, D. A. (1994) Effect of macrophage colony-stimulating factor on anticryptococcal activity of bronchoalveolar macrophages: synergy with fluconazole for killing. Antimicrob. Agents Chemother 38, 2158-2161.
128. 128 Nassar, F. M., Brummer, E. & Stevens, D. A. (1995) Macrophage colony-stimulating factor induction of enhanced anticryptococcal activity in human monocyte-derived macrophages: synergy with fluconazole for killing. Cell Immun. 164, 113-118.
129. 129 Matsumoto, M., et al. (1987) Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice. Chemotherapy 28, 461-479.
130. 130 Pecyk, R. A., Fraser-Smith, E. B. & Matthewa, T. R. (1989) Efficacy of interleukin-1β against systemic Candida albicans infections in normal and immunosuppressed mice. Inject. Immun 57, 3257-3258.
131. 131 Ono, M., Matsumoto, M., Tomioka, S. & Asano, S. (1988) Protective effect of human granulocyte colony-stimulating factor on bacterial and fungal infections in neutropenic mice. Behring Inst Mitt. 83, 216-221.
132. 132 Icki, R., Furuta, T., Asano, S., Mori, S., Kimura, H. & Takaku, F. (1989) Effect of recombinant human granulocyte colony-stimulating factor on Pneumocystis carinii infection in nude mice. Jpn. J. Exp Med. 59, 51-58.
133. 133 Joly, V., Saint Julien, I., Carbon, C. & Yeni, P. (1994) In vivo activity of interferon γ in combination with amphotericin B in the treatment of experimental cryptococcosis. J. Infect. Dis. 170, 1331-1334.
134. 134 Lutz, J. E., Clemens, K. V. & Stevens, D. A. (1996) Synergy between interferon-gamma and antifungal chemotherapy in systemic cryptococcosis. Clin. Infect. Dis. 23, 899.
135. 135 Clemons, K. V., Lutz, J. E. & Stevens, D. A. (1997) Synergistic efficacy of interferon γ and amphotericin B against histoplasmosis. Abstract. Gen. Meet. Am. Soc. Microbiol. 97, 258.
136. 136 Polak, A. (1991) Protective effect of human granulocyte colony stimulating factor on Candida infections in normal and immunosppressed mice. Mycoses 34, 109-118.
137. 137 Polak, A. (1991) Protective effect of human granulocyte colony stimulating factor on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses 34, 205-215.
138. 138 Graybill, J. R., Bocanegra, R., Najvar, L. K., Loebenberg, D. & Luther, M. F. (1998) Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immunosuppression. Antimicrob. Agents Chemother, 42, 2467-2473.
139. 139 Vitt, C. R., Fidler, J. M., Ando, D., Zimmermann, R. J. & Aukermann, S. L. (1994) Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidosis in the rat. J. Infect. Dis. 169, 369-374.
140. 140 Walsh, T. J., de Pauw, B., Anaissie, E. & Martino, P. (1994) Recent advances in the epidemiology, prevention and treatment of invasive fungal infections in neutropenoic patients, J. Med. Vet. Mycol. 32 (Suppl. 1), 33-51.
141. 141 Playford, E. G. & Wells, R. (1996) Treatment of central nervous system aspergillosis with liposomal amphotericin B and gamma interferon in a patient with chronic granulomatous disease. Aust. N. Z. J. Med. 26, 620.
142. 142 Clancy, C. J., Diaz, L. E. & Nguyen, M. H. (1996) Invasive aspergillosis sinusitis in normal hosts: value of adjunctive therapy with interferon gamma. Clin. Infect. Dis. 23, 889.
143. 143 Poynton, C. H., Barnes, R. A. & Rees, J. (1998) Interferon gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia. Clin. Infect. Dis 26, 239-240.
144. 144 Himura, T., Hirayama, T., Banzai, M., Oda, T., Daito, N. & Numazaki, M. (1994) Clinical evaluation of combined use of miconazole and G-CSF on deep-seated mycoses in patients with gynaecological cancers. Jpn J. Antibiot. 47, 428-439.
145. 145 Hennequin, C., Benkerrou, C., Gaillard, J. L., Blanche, S. & Fraitag, S. (1994) Role of granuloryte colony stimulating factor in the management of infection with Fusarium oxysporum in a neutropenic child. Clin. Infect. Dis 18, 490-491.
146. 146 Grauer, M. E., Bokemeyer, C., Bautsch, W., Freund, M. & Limk, H. (1994) Successful treatment of a Trichosporon beigelii septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor. Infection 22, 55-58.
147. 147 Ozsahin, H., von Planta, M., Müller, I., et al. (1998) Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes and liposomal amphotericin B. Blood 92, 2719-2724.
148. 148 Niitsu, N. & Umeda, M. (1996) Fungemia in patients with hematological malignancies: therapeutic effect of concomitant administration of fluconazole and granulocyte-colony-stimulating factor. Chemotherapy 42, 215-219.
149. 149 Gavira, M., Grohskopi, L. A. & Root, R. K. (1997) Successful treatment of rhinocerebral mucormycosis. Probable role for G-CSF. Clin. Infect. 25, 378.
150. 150 Bodey, G. P., Anaissie, E., Gutterman, J. & Vadhan, R. S. (1993) Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infections in patients with cancer. Clin. Infect. Dis. 17, 705-707.
151. 151 Anaissie, E., Wong, E., Bodey, G. P., Obtrien, S., Guttermann, J. & Vadhan, S. (1989) Granulocyte-macrophage colony-stimulating factor plus amphotericin B for disseminated mycoses in neutropenic cancer patients. ICAAC 1989 Houston, Texas. Abstract 73.
152. 152 Martino, P., Meloni. G. & Cassone, A. (1990) Candidal endocarditis and treatment with fluconazole and granulocyte-macrophage colony-stimulating factor. Ann. Int. Med. 112, 966-867.
153. 153 Price, D. A., Klein, J. L., Fisher, M., Main, J., Bingham, J. S. & Coker, R. J. (1997) Potential role for granulocyte-macrophage colony-stimulating factor in the treatment of HIV-associated cryptococcal meningitis. AIDS 11, 693-694.
154. 154 Manfredi, R., Coronado, O. V. & Mastroianni, A. (1997) Liposomal amphotericin B and recombinant human granulocyte-macrophage colony-stimulating factor on the treatment of paediatric AIDS-related cryptococcosis. Int. J. STD AIDS 8, 406-408.
155. 155 Spieberger, R. T., Falleroni, M. J., Coene, A. J. & Larsen, R. A. (1993) Concomitant amphotericin B therapy, granulocyte transfusions and GM-CSF administration for disseminated Fusarium in a granulocytopenic patient. Clin. Infect. Dis. 16, 528-530.
156. 156 Schiller, G., O'Neil, C., Neumunaitis, J., Ando, D. & O'Byrne, J. (1993) A phase II. study of placebo versus recombinant human macrophage colony-stimulating factor to antifungal therapy in patients with invasive Candida or Aspergillus fungal infection. Blood 82 (Suppl. 1), 517a.
157. 157 Laurahanta, J., Zaug, M., Polak, A. & Reinel, D. (1993) Combination of amorolfine with griseofulvin: in vitro activity and clinical results in onychomycosis. JAMA Southeast Asia 9 (Suppl. 4), 23-27.
158. 158 Zaug, M. (1994) International clinical experience in onychomycosis with amorolfine lacquer as mono- or combination therapy. Eighth International Symposium of the Polish Society, Bydgoszcz, Poland. Abstract 6, 15-16.
159. 159 de Feuilhade, M., Baron, R., Goettman, S., et al. (1995) Interest of the combination of 5% amorolfine nail lacquer plus terbinafine tablet in the treatment of foot dermatophyte onychomycosis with involved matrix. J. Eur. Acad. Dermatol. Venerol. 5, S93.
160. 160 de Feuilhade, M., Baron, R., Goettman, S., et al. (1996) Interest of the combination of 5% amorolfine nail lacquer plus terbinafine tablet in the treatment of fool dermatophyte onychomycosis with involved matrix. Clinical Dermatology 2000 Vancouver. Abstract 375.
161. 161 Rakosi, T. (1996) Behandlung der Onychomykose. Eine neue Option der Therapie? Ars Med. 86 (20), 1203-1206.
162. 162 Dole, S., Larnier, C. & Chicoye, A. (1996) Pilot cost-effectiveness analysis of three therapeutical schemes in the treatment of foot dermatophyte onychomycosis with involved matrix. Clinical Dermatology 2000 Vancouver. Abstract 309.
163. 163 Gupta, A. K., Scher, R. K. & De Doncker, P. (1997) Current management of onychomycosis, an overview. Dermatol, Clin. 15, 121-135.